Aurobindo Pharma fined ₹2.56 Crore plus interest and penalty by GST authority
The Appellate Joint Commissioner confirmed a demand for reversal of alleged excess ITC of ₹2.56 Crore, plus ₹1.78 Crore in interest and a ₹25.64 Lakh penalty. The total disputed amount is ₹4.60 Crore. Aurobindo Pharma plans to appeal the order, stating no material financial or operational impact.
Despite the confirmed demand, the company has explicitly stated that there is no material impact on its financials or operations, suggesting the amount is manageable or already provisioned for.
The company has been ordered to pay a significant amount in taxes, interest, and penalties, which is a negative development.
Aurobindo Pharma Limited has announced an order passed by the Appellate Joint Commissioner (ST), Malkajgiri Division, Hyderabad, Telangana. The order confirms a demand for the reversal of alleged excess Input Tax Credit (ITC) amounting to ₹2,56,44,999. This amount comprises CGST of ₹81,04,008, SGST of ₹81,04,008, and IGST of ₹94,36,983.
In addition to the ITC reversal, the order also confirms interest amounting to ₹1,78,19,409 and a penalty of ₹25,64,500. The total disputed amount stands at ₹4,60,28,908. The authority's decision upholds a previous order dated February 28, 2025, which alleged excess ITC claim in GSTR 3B compared to GSTR 2A for the Financial Year 2020-21.
The company received this order on September 28, 2026, at 16:51 Hrs. Aurobindo Pharma intends to file an appeal against this order before the GST Appellate Tribunal. The company has stated that there is no material impact on its financials or operations due to this order.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.